These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 1622443)

  • 1. General pharmacology of the new quinolone antibacterial agent levofloxacin.
    Takasuna K; Kasai Y; Usui C; Takahashi M; Hirohashi M; Tamura K; Takayama S
    Arzneimittelforschung; 1992 Mar; 43(3A):408-18. PubMed ID: 1622443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. General pharmacological profile of the new cognition-enhancing agent nefiracetam.
    Kitano Y; Makino M; Usui C; Takasuna K; Kasai Y; Hirohashi M; Tamura K; Takayama S; Kojima H; Iizuka H
    Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. General pharmacological properties of the new vasodilator flosequinan.
    Ikezono K; Fujita S; Umezato M; Hosoki E; Toba Y; Kusunoki A; Shintani S
    Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. General pharmacology of recombinant human basic fibroblast growth factor.
    Okumura M; Yajima M; Nishimura T; Ikeda H; Nishimori T
    Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General pharmacological properties of the main metabolite of flosequinan.
    Fujita S; Ikezono K; Umezato M; Hosoki E; Toba Y; Ishikawa M; Kusunoki A; Shintani S
    Arzneimittelforschung; 1992 Oct; 42(10):1212-22. PubMed ID: 1335257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).
    Andoh K; Kimura T; Saeki I; Tabata R; Yamazaki S; Eguchi I; Hanazuka M; Horii D; Munt PL; Davis AS
    Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. General pharmacological profile of the new anti-ulcer drug 3-[[[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl]methyl]-amino-N -methylbenzamide.
    Hirohashi M; Takasuna K; Kasai Y; Usui C; Tamura K; Kojima H
    Arzneimittelforschung; 1993 May; 43(5):569-77. PubMed ID: 8329002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological studies on timiperone, a new neuroleptic drug Part II: General pharmacological properties.
    Yamasaki T; Kojima H; Tanaka M; Aibara S; Hirohashi M; Kasai Y; Tsubokawa M; Watanabe K; Akashi A
    Arzneimittelforschung; 1981; 31(4):707-15. PubMed ID: 6113834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. General pharmacology of the new antimuscarinic compound vamicamide.
    Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K
    Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. General pharmacological profiles of the new beta-adrenoceptor antagonist carvedilol.
    Hirohashi M; Takasuna K; Tamura K; Yamaguchi K; Maekawa K; Yamada S; Iwasaki S; Yoshida M; Nomura M; Taguchi K
    Arzneimittelforschung; 1990 Jul; 40(7):735-46. PubMed ID: 1977393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General pharmacological properties of muroctasin.
    Kojima H; Hirohashi M; Kasai Y; Takasuna K; Fukumoto C; Akashi A
    Arzneimittelforschung; 1988 Jul; 38(7A):1002-9. PubMed ID: 3190791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide.
    Saito T; Ukai K; Masuda T; Nakagawa T; Kimura K; Fujii M; Wakatsuki K; Saeki M; Kasai H
    Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties.
    Kito G; Morimoto S; Shiomi M
    Arzneimittelforschung; 1996 Jun; 46(6):572-9. PubMed ID: 8767346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological studies with the alpha 2-adrenoceptor antagonist midaglizole. Part II: Central and peripheral nervous systems.
    Hirohashi M; Takasuna K; Kasai Y; Usui C; Kojima H
    Arzneimittelforschung; 1991 Jan; 41(1):19-24. PubMed ID: 1675569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General pharmacology of beraprost sodium. 2nd communication: effect on the autonomic, cardiovascular and gastrointestinal systems, and other effects.
    Murata T; Murai T; Kanai T; Ogaki Y; Sanai K; Kanda H; Sato S; Kajikawa N; Umetsu T; Matsuura H
    Arzneimittelforschung; 1989 Aug; 39(8):867-76. PubMed ID: 2510743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 2nd communication: effect on the peripheral nervous system and peripheral organs.
    Hirotsu I; Kihara T; Hattori Y; Hatta M; Hirose N; Ishihara T; Satoh F
    Arzneimittelforschung; 1988 Oct; 38(10):1410-7. PubMed ID: 3196381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive and general pharmacological properties of budralazine.
    Chiba T; Shibamura S; Tanaka M; Yamasaki T; Hashimoto H; Kurebayashi Y; Kasai Y; Ryokawa Y; Tamura K; Hirohashi M; Akashi A
    Arzneimittelforschung; 1981; 31(7):1080-7. PubMed ID: 7023495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute oral toxicity of the new quinolone antibacterial agent levofloxacin in mice, rats and monkeys.
    Kato M; Furuhama K; Yoshida M; Akahane K; Takayama S
    Arzneimittelforschung; 1992 Mar; 43(3A):365-6. PubMed ID: 1622433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [General pharmacology of T-3761, a new oral quinolone antibacterial agent (2). Effect on the respiratory and cardiovascular systems, autonomic nervous system and other functions].
    Furuhata K; Hiraiwa T; Terashima N; Arai H; Ono S; Hashiba K; Maekawa M; Kitamura K; Nakada Y; Mori Y
    Jpn J Antibiot; 1995 May; 48(5):706-32. PubMed ID: 7637205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [General pharmacology of traxanox sodium. I. Effects on the central, somatic, and autonomic nervous systems, digestive system, urologic organs, and reproductive system].
    Goto K; Osuga K; Haga K; Tsumagari T
    Nihon Yakurigaku Zasshi; 1983 May; 81(5):343-63. PubMed ID: 6629211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.